Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 32
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04841148 | Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer | ||
| NCT07069595 | PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease | ||
| NCT06774027 | Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer | ||
| NCT07222215 | PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) | ||
| NCT01494662 | HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | ||
| NCT03095352 | Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | ||
| NCT01101425 | Male Breast Cancer: Understanding the Biology for Improved Patient Care | ||
| NCT04443348 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | ||
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT) | ||
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | ||
| NCT07458113 | Sac-TMT for Active TNBC Brain Metastases | ||
| NCT06439693 | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | ||
| NCT00977119 | Investigation of Genetic Determinants of Capecitabine Toxicity | ||
| NCT06551116 | QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | ||
| NCT01982448 | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | ||
| NCT03501979 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | ||
| NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") | ||
| NCT05721248 | STOP-HER2: Stopping Trastuzumab in HER2+ MBC | ||
| NCT06533826 | TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | ||
| NCT02743910 | Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer | ||
| NCT00577122 | Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer | ||
| NCT05501704 | ETHAN - ET for Male BC | ||
| NCT00146536 | Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy | ||
| NCT07340541 | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies | ||
| NCT02384239 | A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | ||
| NCT01937117 | Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | ||
| NCT00999804 | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | ||
| NCT04584255 | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | ||
| NCT02928978 | Ruxolitinib for Premalignant Breast Disease | ||
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | ||
| NCT03368729 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | ||
| NCT00925652 | Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer |
